Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
The company is still looking to bounce back after the beating it took in recent years.
Overview
Several years ago, Novo Nordisk (NYSE: NVO) -- which is now branding itself as Novo -- was performing so well that it was improving the entire economy of its home country, Denmark. The company was riding the wave of soaring demand for its GLP-1 medicines, Wegovy and Ozempic. However, Novo Nordisk has lost significant market value due to stiff competition in its core market, primarily from a single company, Eli Lilly (NYSE: LLY).
Here's even worse news: Over the next few years, more GLP-1 therapies will enter the market seeking to challenge Novo Nordisk. Can the company remain a leader in this industry and perform well over the medium term? Let's find out where Novo Nordisk might be in five years.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.